Multiple myeloma: Treatment evolution

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  San Miguel, Jesus F ^a   Mateos, Maria Victoria ^a   Ocio, Enrique ^a   Garcia Sanz, Ramón ^a  

^a Centro de Investigacion del Cancer   (Spain)

Author keywords

Allogeneic transplant; Autologous transplant; Immunomodulatory drugs; Proteasome inhibitors

Indexed keywords

ATIPRIMOD; BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; HISTONE DEACETYLASE INHIBITOR; INTERFERON; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PERIFOSINE; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; TIPIFARNIB; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GERIATRIC PATIENT; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MELPHALAN; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; YOUNG ADULT;

EID: 84859738459     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169154971     Document Type: Article

References (10)

1. San-Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008;26(16):2761-6.
2. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet. 2010;376:2075-85.
3. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol. 2010;11:9-37.
4. San Miguel J, Schlag R, Khuageva N, et al. A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with Melphalan-Prednisone (MP) in newly diagnosed multiple myeloma. N Engl J Med. 2008;359(9):906-17.
5. Stewart K, Richardson P, San Miguel J. How I treat multiple myeloma in younger patients. Blood. 2009;114(27):5436-43.
6. Ludwig H, Bolejack V, Crowley J. Bladé J, Miguel JS, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599-605.
7. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, et al. InternationalMyeloma WorkingGroup consensus statement regarding the current status of allogeneic transplantation for multiple myeloma. J Clin Oncol. 2010;28(29):4521-30.
8. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495-502.
9. Lahuerta JJ, Mateos MV, Martines-Lopez J, Rosiñol L, Sureda A, de la Rubia J, et al. Influence of pre-and post transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775-82.
10. Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognosis subgroup of symptomatic multiple myeloma patients. Blood. 2009;114(20):4369-72.